Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs Spruce Biosciences, Inc. (SPRB)

Coherus Oncology, Inc. and Spruce Biosciences, Inc. are both Biotechnology companies. Spruce Biosciences, Inc. is the larger, with a market value of $133.8M against $119.0M — 1.1× the size. Coherus Oncology, Inc. grew revenue faster over the last twelve months: 61.0% against −51.3%. Spruce Biosciences, Inc. has the higher net margin (0.00% vs −259.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Spruce Biosciences, Inc. leads on 10 and Coherus Oncology, Inc. on 7.

Valuation

Metric CHRS SPRB Biotechnology median
P/E n/m n/m 10.60
P/S 2.34 23.04 9.40
P/B 1.96 1.35 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 4.44 4.88 9.02
Earnings yield (133.77%) (88.60%) (32.88%)
Free cash flow yield (156.84%) (37.80%) (23.13%)

Profitability

Metric CHRS SPRB Biotechnology median
Gross margin 68.94% 100.00% 68.51%
Operating margin (311.56%) 0.00% 0.00%
Net margin (259.41%) 0.00% 0.00%
Free cash flow margin (365.22%) 0.00% 0.00%
Return on equity (146.27%) (105.98%) (51.96%)
Return on assets (41.90%) (82.38%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CHRS SPRB Biotechnology median
Revenue growth (TTM) 61.00% (51.32%) 6.76%
EPS growth (last fiscal year) 472.00% 47.59% 29.88%
Revenue growth, 5-year CAGR (38.41%) — 9.75%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS SPRB Biotechnology median
Debt to equity 0.61 0.08 0.00
Current ratio 1.77 9.23 4.97
Net debt to EBITDA 0.76 1.34 1.01

Dividend

Metric CHRS SPRB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CHRS SPRB Biotechnology median
Market cap 118.97m 133.79m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack